Evidence map›Paper›PMID 38881188›Full record

ArticleCancer research communications2024

Generation, Transcriptomic States, and Clinical Relevance of CX3CR1+ CD8 T Cells in Melanoma.

Hirohito Ishigaki, Takayoshi Yamauchi, Mark D Long, Toshifumi Hoki, Yuta Yamamoto, Takaaki Oba, Fumito Ito

Abstract read
In one paragraph

Article in Cancer research communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. CX3CR1Cancer science · 2024
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hirohito Ishigaki *Department of Surgery, University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, California.ORCID 0000-0002-5249-8598
Takayoshi Yamauchi *Department of Surgery, University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, California.ORCID 0000-0002-5685-7658
Mark D LongDepartment of Biostatistics & Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, New York.ORCID 0000-0003-1120-8176
Toshifumi HokiCenter for Immunotherapy, Roswell Park Comprehensive Cancer Center, Buffalo, New York.ORCID 0000-0002-8853-4167
Yuta YamamotoDepartment of Surgery, University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, California.ORCID 0000-0003-1225-2240
Takaaki ObaCenter for Immunotherapy, Roswell Park Comprehensive Cancer Center, Buffalo, New York.ORCID 0000-0001-8283-4989
Fumito ItoDepartment of Surgery, University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, California.ORCID 0000-0002-6866-671X

Funding

Two-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MARK G FRATTINI · 1985 to 2026
$116.6M
In situ radioimmunotherapy to maximize the engagement of conventional type 1 dendritic cells against non-T cell-inflamed tumorsR01CA255240 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ITO, FUMITO · 2021 to 2025
$2.0M
Adoptive Cell Therapy with Rejuvenated Antigen-Specific T CellsK08CA197966 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ITO, FUMITO · 2015 to 2019
$875k
NCI NIH HHS K08 CA197966NCI NIH HHS P30 CA016056NCI NIH HHS R01 CA255240
6 · The paper itself

Abstract

Recent progress in single-cell profiling technologies has revealed significant phenotypic and transcriptional heterogeneity in tumor-infiltrating CD8+ T cells. However, the transition between the different states of intratumoral antigen-specific CD8+ T cells remains elusive. Here, we sought to examine the generation, transcriptomic states, and the clinical relevance of melanoma-infiltrating CD8+ T cells expressing a chemokine receptor and T-cell differentiation marker, CX3C chemokine receptor 1 (CX3CR1). Analysis of single-cell datasets revealed distinct human melanoma-infiltrating CD8+ T-cell clusters expressing genes associated with effector T-cell function but with distinguishing expression of CX3CR1 or PDCD1. No obvious impact of CX3CR1 expression in melanoma on the response to immune checkpoint inhibitor therapy was observed while increased pretreatment and on-treatment frequency of a CD8+ T-cell cluster expressing high levels of exhaustion markers was associated with poor response to the treatment. Adoptively transferred antigen-specific CX3CR1- CD8+ T cells differentiated into the CX3CR1+ subset in mice treated with FTY720, which inhibits lymphocyte egress from secondary lymphoid tissues, suggesting the intratumoral generation of CX3CR1+ CD8+ T cells rather than their trafficking from secondary lymphoid organs. Furthermore, analysis of adoptively transferred antigen-specific CD8+ T cells, in which the Cx3cr1 gene was replaced with a marker gene confirmed that CX3CR1+ CD8+ T cells could directly differentiate from the intratumoral CX3CR1- subset. These findings highlight that tumor antigen-specific CX3CR1- CD8+ T cells can fully differentiate outside the secondary lymphoid organs and generate CX3CR1+ CD8+ T cells in the tumor microenvironment, which are distinct from CD8+ T cells that express markers of exhaustion. SIGNIFICANCE: Intratumoral T cells are composed of heterogeneous subpopulations with various phenotypic and transcriptional states. This study illustrates the intratumoral generation of antigen-specific CX3CR1+ CD8+ T cells that exhibit distinct transcriptomic signatures and clinical relevance from CD8+ T cells expressing markers of exhaustion.

Indexed as

CD8-Positive T-LymphocytesCX3C Chemokine Receptor 1Lymphocytes, Tumor-InfiltratingMelanomaTranscriptomeAnimalsClinical RelevanceFingolimod HydrochlorideHumansImmune Checkpoint InhibitorsMiceMice, Inbred C57BLSingle-Cell AnalysisCX3C Chemokine Receptor 1CX3CR1 protein, humanFingolimod HydrochlorideImmune Checkpoint Inhibitors

Identifiers

PMID38881188
PMCPMC11267618

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.